Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment
Status:
COMPLETED
Trial end date:
2023-09-03
Target enrollment:
Participant gender:
Summary
Phase III interventional study to evaluate the different efficacy of Torasemide and Spironolactone in reducing systolic blood pressure in carriers and non-carriers of the different genotypic combinations for Lanosterol and Uromodulin